Skip to content

Revvity RVTY Human Health — Intangible Impairment

Discontinued — last reported Q4 '13

Similar metrics at other companies

Chart Industries logo
GTLSBiomedical — Intangible Impairment
$9.53M
Leidos Holdings logo
LDOSHealthand Infrastructure — Intangible Impairment
$0-100%
IR
IRMedical — Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
$3.7M
VMI
VMIInfrastructure — Intangible Impairment
$19.66M
Antero Midstream Corporation logo
AMWater Handling — Intangible Impairment
$6M
Baxter International logo
BAXHospital Products — Intangible Impairment
$41M

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.

The official record: Revvity’s 10-K, filed March 1, 2016, on SEC EDGAR. View the filing →

Questions, answered.

What does human health — intangible impairment mean?
The write-down of the value of finite-lived intangible assets within the Human Health segment due to reduced expected future value.
How do you interpret human health — intangible impairment?
An increase signals a loss of value in specific intellectual property or customer contracts, indicating potential operational or market headwinds.
How does human health — intangible impairment compare across companies?
Comparable to 'Impairment of Finite-Lived Intangibles' reported by pharmaceutical and diagnostic peers.